Over time, that can lead to fatigue, irritability, poor concentration, and even increased risk for chronic health conditions like heart disease and diabetes
In fact, as research in recent years clarified the central role of disordered metabolism in NAFLD, experts proposed a new name for the condition: metabolic dysfunction-associated fatty liver disease (MAFLD)
This extra action makes retatrutide a more advanced option for treating type 2 diabetes and obesity by helping your body release more insulin, curb your appetite, and burn more energy
Why this trial matters: First triple hormone receptor agonist showing major Phase III weight-loss efficacy Delivers weight-loss outcomes far beyond many current therapies Suggests a potential new metabolic and obesity care benchmark Semaglutide Shows Consistent Liver Benefits in MASH In the Phase III ESSENCE study, once-weekly semaglutide 2.4 mg significantly increased rates of steatohepatitis resolution and fibrosis improvement on liver biopsy in adults with metabolic dysfunction-associated steatohepatitis (MASH), compared with placebo
Impact on Intestinal Peristalsis Modulating Gut Motility One significant impact of GLP-1 receptor agonists like Ozempic is their effect on intestinal peristalsisthe wave-like contractions that propel food through the digestive tract